Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so ...

BIOSPAIN showed how partnering conferences connect public funding, venture capital, and pharma to drive biotech innovation to ...

The Asabys-Aliath integration signals how European biotech VCs are scaling and adapting amid funding pressures.

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS).

The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision to back out of its $1 billion ...

Asthma affects around 260 million people worldwide, making it one of the most common chronic respiratory conditions. Despite advances in treatment, it still contributes to hundreds of thousands of ...

Until now, Barth syndrome, a fatal genetic condition that affects the heart and muscles, was deemed untreatable. The first therapy has been greenlit by U.S. regulators, as it was able to improve ...